AzTrials
AzTrials

Heart FailureNCT00586833

Heart Failure and a Preserved Ejection Fraction

An observational study of Heart Failure, run by Mayo Clinic at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This will be a cross sectional study comparing patients with HFpEF and age-matched, non-HF controls recruited from the community. This design will allow for determination of biologically relevant differences in baseline ventricular and vascular function, and importantly, differences in the ability to augment… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
O2 consumption max bike test
Type of treatment
Surgery or procedure
How many people
51 participants
Where
1 siteUnited States
Study dates
Apr 2007to Jun 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.3 There are currently >350 pre-identified subjects with HFpEF from this study who may be eligible, which will greatly enrich the recruiting process. Control Subjects will be recruited from the community. Control subjects will be matched for age and gender to HFpEF subjects, but will have no history of HF hospitalization or significant exertional dyspnea suggestive of "preclinical" HF.

Who may be able to join

  • Consultation by a cardiologist for HF in the past 1 year
  • (HF rigorously defined by the modified Framingham criteria9),
  • able to exercise on a treadmill

Who cannot join

  • decompensated HF; significant valvular disease; infiltrative, restrictive, or hypertrophic cardiomyopathy; cor pulmonale or significant pulmonary limitation; unstable coronary disease; atrial fibrillation; pregnancy; inability to exercise or suspend vasoactive medicines for at least 24 hours

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Mayo Clinic

    Rochester, Minnesota, 55905

Other trials in United States

About this study

Official title: The Role of Vascular Dysfunction in Limiting Cardiovascular Reserve in Patients With Heart Failure and a Preserved Ejection Fraction

This will be a cross sectional study comparing patients with HFpEF and age-matched, non-HF controls recruited from the community. This design will allow for determination of biologically relevant differences in baseline ventricular and vascular function, and importantly, differences in the ability to augment ventricular and vascular function dynamically during exercise stress, when symptoms of HF typically are first noted. The endpoint of exercise-reserve function is novel and has been little examined in the existing HFpEF literature.

Read the detailed description

Congestive heart failure (HF) is the leading cause of hospitalization among older Americans.1 Approximately half of affected patients have apparently normal systolic function (HF with preserved ejection fraction, HFpEF).2-4 In contrast to HF with low EF, there are no proven treatments for HFpEF, due largely to a lack of mechanistic understanding.4 HFpEF patients are typically older, hypertensive and female,2,3 and each of these characteristics is associated with vascular stiffening and dysfunction.5-7 Diastolic abnormalities may contribute to symptoms of exertional intolerance3,8, but non-cardiac limitations have recently been shown to be equally important.9-11 Patients with HFpEF display impaired decreases in mean vascular resistance in response to exercise, significantly limiting performance,9 yet this represents only one component of ventricular afterload. With aging and particularly in HFpEF, pulsatile load due to vascular stiffening and increased wave reflections becomes more magnified.6,12 The latter can be quantified by pulse wave velocity, arterial compliance and carotid augmentation index. These can be determined noninvasively, and while they have been shown to be abnormal in HFpEF patients at rest10,11, little is known about changes in each during exercise stress, or how this might modulate ventricular performance. Recent evidence indicates that endothelial and autonomic dysfunction are present in HFpEF9, but it is not known how these abnormalities might limit ventricular-vascular function with exercise. The primary objective of this proposal is to compare resting and exercise-induced changes in vascular function in patients with HFpEF and age-matched controls, to determine how these factors may affect exercise performance and cardiovascular reserve function.

Specific Aim 1. Contrast resting and exercise-induced changes in vascular stiffness, endothelial function, and afterload in patients with HFpEF to age-matched controls. Net, mean, and late components of afterload will be assessed by arterial elastance (Ea), systemic vascular resistance (SVR), and central augmentation index (AI). Vascular stiffness will be quantified by pulse wave velocity and total arterial compliance. Stiffness and afterload are dynamically modulated by endothelial and autonomic function, and these responses will be assessed by finger volume plethysmography. Parameters will be measured at rest, during upright cycle ergometry, and immediately post exercise by noninvasive blood pressure, tonometry and comprehensive echo-Doppler examination with tissue Doppler echo (TDE).

Specific Aim 2. Determine how baseline and exercise-induced changes in the vascular parameters measured in specific aim 1 are related to LV systolic and diastolic functional reserve, cardiac output response, metabolic exercise performance, and changes in pulmonary capillary blood volume. LV systolic and diastolic function will be assessed by echo-Doppler and TDE parameters at rest and immediately after peak exercise. Cardiac output response will be determined by the product of echo-Doppler stroke volume and heart rate. Exercise performance will quantified by expired gas analysis. Pulmonary blood volume will be estimated based upon the ratio of diffusion capacity of nitric oxide and carbon monoxide, obtained both at rest and immediately post exercise. Regression analyses will then be performed using the measured components of afterload and vascular stiffness as the independent variable and each of the above parameters as dependent output variables to delineate the role of vascular stiffening on exercise performance, reserve and ventricular-vascular coupling.

Specific Aim 3. Determine if vascular and ventricular stiffness properties measured in specific aim 1 are associated with abnormal neurohormonal responses to exercise. Blood samples will be obtained from HFpEF subjects and controls prior to and immediately after peak exercise to contrast exercise-induced changes in B-type natriuretic peptide levels and cyclic guanosine monophosphate levels.

Conditions
Heart Failure
Being tested
O2 consumption max bike test
Keywords
Heart Failure, Heart Failure, Diastolic, Dyspnea, Paroxysmal, Edema, Cardiac
Medical subject headings
Heart Failure, Heart Failure, Diastolic, Dyspnea, Paroxysmal, Edema, Cardiac

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • O2 consumption max bike testProcedure or surgery

    Also called Standard metabolic stress testing., Pulmonary Capillary Blood Volume., Plasma and Serum Neurohormone levels., Ventricular data determined from echo-Doppler.

    Single visit exercise study

Study groups in NCT00586833
Study groupRoleWhat they receive
1No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
Receives: Procedure: O2 consumption max bike test
2CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
Receives: Procedure: O2 consumption max bike test
3 Healthy normal adultsNo identifiable cardiac issues at time of exercise.
Receives: Procedure: O2 consumption max bike test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Contrast resting and exercise-induced changes in vascular stiffness, endothelial function, and afterload in patients with HFpEF to age-matched controls.

    Measured: Throughout single visit.

Secondary outcomes (2)
  1. Determine how baseline and exercise-induced changes in the vascular parameters measured are related to LV systolic and diastolic functional reserve, cardiac output response, metabolic exercise performance, and changes in pulmonary cap

    Measured: Throughout single visit

  2. Determine if vascular and ventricular stiffness properties measured in specific aim 1 are associated with abnormal neurohormonal responses to exercise.

    Measured: Immediately pre and post exercise

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2008 (estimated)
  2. Study startApr 2007
  3. Primary completionJun 2009
  4. Study completionJun 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
51 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00586833
Sponsor's protocol ID
07-001301
Other IDs
CHF
Status last verified
Oct 2010
First submitted
21 Dec 2007
Last updated
14 Oct 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Failure, run by Mayo Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Contrast resting and exercise-induced changes in vascular stiffness, endothelial function, and afterload in patients with HFpEF to age-matched controls. (time frame: Throughout single visit.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2010.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in